FTSV - DAILY CHARTHi, today we are going to talk about Forty Seven and its current landscape.
Forty Seven company receives attention today as the Cancer - Drug Race heats up, in the middle a day of the announcements of a $5.2 billion total in Acquisitions by big names of the pharmaceuticals sector, such as Merck & Co. and Sanofi, that had made strategic movements on the oncology sector. Forty Seven isn't different since the company today unveiled that its monoclonal antibody against CD47 drug, named Magrolimab, has shown a complete response rate of 50% and an overall response rate of 92% observed in untreated patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia, during its trials, robust results that put the company in evidence today.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
